1/15
08:00 am
coll
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
Low
Report
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
1/14
05:36 am
coll
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 [Yahoo! Finance]
Low
Report
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 [Yahoo! Finance]
1/12
11:57 am
coll
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? [Yahoo! Finance]
Low
Report
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? [Yahoo! Finance]
1/10
07:02 pm
coll
Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? [Yahoo! Finance]
Medium
Report
Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? [Yahoo! Finance]
1/10
08:38 am
coll
Is It Time To Reassess Collegium Pharmaceutical (COLL) After Its Strong Five Year Share Price Run? [Yahoo! Finance]
Medium
Report
Is It Time To Reassess Collegium Pharmaceutical (COLL) After Its Strong Five Year Share Price Run? [Yahoo! Finance]
1/9
10:26 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its price target lowered by analysts at Barclays PLC from $58.00 to $56.00. They now have an "overweight" rating on the stock.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its price target lowered by analysts at Barclays PLC from $58.00 to $56.00. They now have an "overweight" rating on the stock.
1/9
08:02 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its price target raised by analysts at Needham & Company LLC from $48.00 to $56.00. They now have a "buy" rating on the stock.
Medium
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its price target raised by analysts at Needham & Company LLC from $48.00 to $56.00. They now have a "buy" rating on the stock.
1/9
07:18 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/8
08:00 am
coll
Collegium Provides 2026 Financial Guidance and Business Update
Medium
Report
Collegium Provides 2026 Financial Guidance and Business Update
1/8
06:15 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/7
09:07 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) was given a new $55.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) was given a new $55.00 price target on by analysts at Truist Financial Corporation.
12/30
08:00 am
coll
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
Medium
Report
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
12/29
06:47 pm
coll
2 Reasons to Avoid COLL and 1 Stock to Buy Instead [Yahoo! Finance]
Medium
Report
2 Reasons to Avoid COLL and 1 Stock to Buy Instead [Yahoo! Finance]
12/24
10:15 am
coll
3 Cash-Producing Stocks We Think Twice About [Yahoo! Finance]
Low
Report
3 Cash-Producing Stocks We Think Twice About [Yahoo! Finance]
12/23
07:41 am
coll
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors [Yahoo! Finance]
Low
Report
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors [Yahoo! Finance]
12/22
11:03 am
coll
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? [Yahoo! Finance]
Low
Report
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? [Yahoo! Finance]
12/20
07:19 am
coll
Is Strong Q3 Beat And Higher Guidance Altering The Investment Case For Collegium Pharmaceutical (COLL)? [Yahoo! Finance]
Low
Report
Is Strong Q3 Beat And Higher Guidance Altering The Investment Case For Collegium Pharmaceutical (COLL)? [Yahoo! Finance]
12/19
07:37 am
coll
3 Unpopular Stocks We Find Risky [Yahoo! Finance]
Low
Report
3 Unpopular Stocks We Find Risky [Yahoo! Finance]
12/10
07:17 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/8
06:07 pm
coll
Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
12/6
02:21 pm
coll
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]
Low
Report
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]
11/25
01:49 pm
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
07:31 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
11/20
05:43 am
coll
Collegium (COLL) Raises 2025 Revenue Guidance—Is Profitability Momentum Built to Last? [Yahoo! Finance]
Low
Report
Collegium (COLL) Raises 2025 Revenue Guidance—Is Profitability Momentum Built to Last? [Yahoo! Finance]
11/19
01:17 pm
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.